Baird’s Michael Ha on how to navigate health insurance stocks in the current downturn
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Michael Ha, Baird, joins ‘Closing Bell Overtime’ to talk health insurance stocks remaining under pressure following the latest Medicare rate announcement from the White House. 05:11 Tue, Jan 27 20264:54 PM EST Source link
‘Fast Money’ traders on how to play Sarepta after report FDA asked it to stop gene therapy shipments
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Fast Money The ‘Fast Money’ traders recap the recent news moving Sarepta lower and how to play the stock from here. 02:45 Fri, Jul 18 20255:39 PM EDT Source link
Regulatory barriers are forcing drug discovery to move to China
Five years ago, U.S. pharmaceutical companies didn’t license any new drugs from China. By 2024, one-third of their new compounds were coming from Chinese biotechnology firms. Why are U.S. drugmakers sending their business to China? As in many other industries, it’s so much cheaper to synthesize new compounds inside Chinese biotechnology firms once a novel […]
How to think about Trump’s pharma tariffs — before they hit
Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. For weeks, President Trump has made it clear that tariffs are going to be slapped on pharmaceuticals. But that is about the only thing that is clear. For the moment, his administration has opened a […]
How to Ride the Biotech Roller Coaster
With stocks starting to price in interest-rate cuts next year, the biotech sector has emerged as a winner for investors seeking riskier bets with more distant payoffs. But investing in this industry is tricky because biotech is a sector of haves and have-nots. While every industry has its winners and losers, the gap in biotech […]